导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.46% | 2627/4773 |
| 近一周 | -2.28% | 1660/5462 |
| 近一月 | -4.26% | 2336/5421 |
| 近一季 | -7.56% | 2449/5209 |
| 近半年 | -2.55% | 1948/4920 |
| 近一年 | 1.08% | 2410/4366 |
| 近两年 | 48.58% | 1520/2954 |
| 近三年 | 30.24% | 1048/2253 |
| 成立以来 | 31.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.62% 3314/4961 |
12.90% 2099/5312 |
- - |
- - |
| 2025 | 20.64% 2103/4813 |
-1.03% 2546/3635 |
2.33% 1646/4076 |
19.00% 2208/4524 |
0.11% 2211/4813 |
| 2024 | 17.97% 632/3463 |
3.02% 636/2808 |
-1.04% 902/3014 |
17.80% 1116/3129 |
-1.77% 1823/3463 |
| 2023 | -9.02% 1090/2656 |
4.62% 909/2280 |
-4.03% 1019/2385 |
-2.91% 788/2515 |
-6.67% 1865/2655 |
| 2022 | -19.89% 912/2207 |
-14.50% 953/1919 |
7.26% 501/2016 |
-14.27% 1057/2113 |
1.88% 1101/2208 |
| 2021 | -3.34% 901/1822 |
-3.16% 769/1255 |
4.52% 878/1330 |
-5.83% 868/1466 |
1.41% 942/1822 |
| 2020 | 29.46% 535/1250 |
-10.29% 769/1028 |
13.95% 581/1067 |
11.49% 443/1164 |
13.58% 349/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 泰康沪深300ETF VS. 长安沪深300非周期A(740101) |